Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ampsource Biopharma Shanghai Inc. has 1 pending office action. The portfolio involves 1 distinct examiner and 0 distinct art units, indicating a focused prosecution effort. The absence of distinct art units suggests that the application is being handled by a single examiner without broader unit distribution. This 1 pending office action represents the total active workload for the company.
Sydney Van Druff is the busiest examiner, managing the 1 pending office action. As the only one of the 1 distinct examiners involved, Sydney Van Druff is responsible for the entire current pending matter. The 1 busiest examiner pending action assigned to this examiner constitutes the full extent of the company's active prosecution at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575642 | ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575642 | ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF | VAN DRUFF, SYDNEY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575642 | ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF | VAN DRUFF, SYDNEY | — | §102§112 | Non-Final OA | — | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial